Program
olokizumab
Also written as “CDP6038”, “Olokizumab” and “OKZ q4w”.
Its studies are mostly in Arthritis, Rheumatoid · COVID-19 · Polymyalgia Rheumatica · Arthritis, Juvenile · Lung Diseases, Interstitial, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| R-Pharm | 113 open or running | phase 3since Apr 29, 2016 | Apr 29, 2016 | Apr 9, 2027phase 3 · NCT06440746 |
| UCB | 80 open or running | phase 2since Nov 4, 2009 | Nov 4, 2009 | none ahead |
Also a collaborator on its studies: keystat-llc, exacte-labs-llc, data-management-365, iqvia-pvt-ltd, quintiles-inc, k-research-llc, cromos-pharma-llc and covance.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 4, 2009.
- Jan 11, 2011Phase 1 study in PharmacokineticsUCB · NCT01276119 · 67 enrolled · Germany
- Feb 14, 2011Phase 2 study in Arthritis, RheumatoidUCB · NCT01296711 · 190 enrolled · United States, Belgium, United Kingdom
- Oct 27, 2011Phase 2 study in Arthritis, RheumatoidUCB · NCT01463059 · 119 enrolled · Japan, Korea, Republic of, Taiwan
- Feb 10, 2012Phase 2 study in Arthritis, RheumatoidUCB · NCT01533714 · 103 enrolled · Japan, Korea, Republic of, Taiwan
- Jul 3, 2012Phase 2 study in Crohn DiseaseUCB · NCT01635621
- Apr 29, 2016R-Pharm's first studies: 3 phase 3 studies in Arthritis, RheumatoidNew to R-PharmR-Pharm · NCT02760433, NCT02760407, NCT02760368
- Feb 7, 2017Phase 3 study in Arthritis, RheumatoidR-Pharm · NCT03120949 · 2,106 enrolled · United States, Argentina, Belarus and more
- Jan 27, 2020Phase 1 study in Arthritis, RheumatoidR-Pharm · NCT04246762 · 17 enrolled · Bulgaria, Moldova, Republic of
- May 6, 2020Phase 3 study in COVID-19R-Pharm · NCT04380519 · 372 enrolled · Russian Federation
- Jun 25, 2020Phase 3 study in COVID-19R-Pharm · NCT04452474
- Dec 24, 2021Phase 3 study in COVID-19R-Pharm · NCT05187793 · 198 enrolled · Russian Federation
- May 28, 2024Phase 3 study in Lung Diseases, InterstitialR-Pharm · NCT06440746 · 138 planned · Russian Federation
- Dec 30, 2025Phase 2 study in Arthritis, JuvenileR-Pharm · NCT07517575 · 71 planned · Russia
- Jun 19, 2026Phase 3 study in Polymyalgia RheumaticaR-Pharm · NCT07670546 · 125 enrolled · Russia
Ahead
- Apr 9, 2027Primary completion: phase 3 study in Lung Diseases, InterstitialR-Pharm · NCT06440746
TargetBeta
“A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (IL-6), ”NCIt, by rule
“Interleukin-6 inhibitor”ChEMBL 37, by rule
Other programs on IL6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ziltivekimabrule | Novo Nordisk | phase 3 | 12 |
| clazakizumab | CSL | phase 3 | 10 |
| pacibekitugrule | Novartis | phase 3 | 1 |
| isomyosaminerule | tnf-pharmaceuticals-inc | phase 2 | 1 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07670546Polymyalgia Rheumatica · Russia | 3 | Active, not recruiting | R-Pharm | Apr 10, 2026 | 125 |
| NCT07517575Arthritis, Juvenile · Russia | 2 | Recruiting | R-Pharm | Sep 2026 | 71 |
| NCT06440746Lung Diseases, Interstitial · Russian Federation | 3 | Recruiting | R-Pharm | Apr 9, 2027 | 138 |
| NCT05187793COVID-19 · Russian Federation | 3 | UNKNOWN | R-Pharm | Oct 31, 2022 | 198 |
| NCT04452474COVID-19 | 3 | Withdrawn | R-Pharm | Nov 16, 2020 | 0 |
| NCT04380519COVID-19 · Russian Federation | 3 | Completed | R-Pharm | Jul 10, 2020 | 372 |
| NCT04246762Arthritis, Rheumatoid · Bulgaria, Moldova, Republic of | 1 | Completed | R-Pharm | Jun 8, 2022 | 17 |
| NCT03120949Arthritis, Rheumatoid · United States, Argentina, Belarus and more | 3 | Completed | R-Pharm | Sep 1, 2021 | 2,106 |
| NCT02760433Arthritis, Rheumatoid · United States, Argentina, Brazil and more | 3 | Completed | R-Pharm | Sep 12, 2019 | 368 |
| NCT02760407Arthritis, Rheumatoid · United States, Argentina, Brazil and more | 3 | Completed | R-Pharm | Aug 2, 2019 | 1,648 |
| NCT02760368Arthritis, Rheumatoid · Belarus, Bulgaria, Russian Federation | 3 | Completed | R-Pharm | Aug 2018 | 428 |
| NCT01635621Crohn Disease | 2 | Withdrawn | UCB | Aug 2013 | 0 |
| NCT01533714Arthritis, Rheumatoid · Japan, Korea, Republic of, Taiwan | 2 | Terminated | UCB | Nov 27, 2013 | 103 |
| NCT01463059Arthritis, Rheumatoid · Japan, Korea, Republic of, Taiwan | 2 | Completed | UCB | Feb 2013 | 119 |
| NCT01296711Arthritis, Rheumatoid · United States, Belgium, United Kingdom | 2 | Terminated | UCB | May 1, 2013 | 190 |
| NCT01276119Pharmacokinetics · Germany | 1 | Completed | UCB | Oct 2009 | 67 |
| NCT01262794Healthy Volunteers · United Kingdom | 1 | Completed | UCB | Sep 2011 | 20 |
| NCT01242488Arthritis, Rheumatoid · United States, Belgium, United Kingdom | 2 | Completed | UCB | Jun 2012 | 221 |
| NCT01009242Arthritis · United States, Germany | 2 | Completed | UCB | Sep 2010 | 40 |
How it is read
Names in the registry
- “CDP6038”, 13 entries
- “Olokizumab”, 5 entries
- “OKZ q4w”, 2 entries
- “CDP6038 (olokizumab)”, 2 entries
- “Olokizumab 64 mg”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 10 studies
- COVID-19, 3 studies
- Polymyalgia Rheumatica, 1 study
- Arthritis, Juvenile, 1 study
- Lung Diseases, Interstitial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.